Merck & Company Inc. (NYSE: MRK) stock closed at 92.51 per share at the end of the most recent trading day (a 0.67% change compared to the prior day closing price) with a volume of 8.43M shares and market capitalization of 233.94B. Is a component of S&P 500, Dow Jones 30, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 74000 people. Merck & Company Inc. CEO is Robert M. Davis.

The one-year performance of Merck & Company Inc. stock is 19.01%, while year-to-date (YTD) performance is 20.71%. MRK stock has a five-year performance of 44.34%. Its 52-week range is between 70.89 and 95.72, which gives MRK stock a 52-week price range ratio of 87.07%

Merck & Company Inc. currently has a PE ratio of 16.70, a price-to-book (PB) ratio of 5.76, a price-to-sale (PS) ratio of 4.42, a price to cashflow ratio of 13.80, a PEG ratio of 2.32, a ROA of 14.74%, a ROC of 22.77% and a ROE of 42.76%. The company’s profit margin is 25.87%, its EBITDA margin is 37.10%, and its revenue ttm is $53.98 Billion , which makes it $21.35 revenue per share.

Of the last four earnings reports from Merck & Company Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $1.68 for the next earnings report. Merck & Company Inc.’s next earnings report date is 28th Jul 2022.

The consensus rating of Wall Street analysts for Merck & Company Inc. is Moderate Buy (2), with a target price of $92.53, which is +0.02% compared to the current price. The earnings rating for Merck & Company Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Merck & Company Inc. has a dividend yield of 2.92% with a dividend per share of $2.76 and a payout ratio of 104.00%.

Merck & Company Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 7.97, ATR14 : 2.09, CCI20 : 89.24, Chaikin Money Flow : 0.03, MACD : 0.74, Money Flow Index : 58.93, ROC : 6.11, RSI : 59.22, STOCH (14,3) : 74.66, STOCH RSI : 0.54, UO : 59.00, Williams %R : -25.34), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Merck & Company Inc. in the last 12-months were: Arpa Garay (Option Excercise at a value of $223 559), Caroline Litchfield (Option Excercise at a value of $144 559), Caroline Litchfield (Sold 18 335 shares of value $1 668 503 ), David Michael Williams (Option Excercise at a value of $180 590), Dean Y. Li (Option Excercise at a value of $161 854), Frank Clyburn (Option Excercise at a value of $207 622), Frank Clyburn (Sold 39 762 shares of value $3 493 879 ), Jannie Oosthuizen (Option Excercise at a value of $223 559), Julie L. Gerberding (Option Excercise at a value of $0), Julie L. Gerberding (Sold 192 540 shares of value $16 925 364 ), Kenneth C. Frazier (Option Excercise at a value of $0), Kenneth C. Frazier (Sold 663 881 shares of value $54 611 361 ), Lisa LeCointe-Cephas (Option Excercise at a value of $167 192), Michael A Klobuchar (Option Excercise at a value of $221 642), Richard R. DeLuca (Option Excercise at a value of $0), Richard R. DeLuca (Sold 165 187 shares of value $14 548 563 ), Rita A. Karachun (Option Excercise at a value of $244 023), Rita A. Karachun (Sold 25 000 shares of value $2 211 215 ), Sanat Chattopadhyay (Option Excercise at a value of $0), Sanat Chattopadhyay (Sold 24 619 shares of value $2 149 731 ), Steven C. Mizell (Option Excercise at a value of $415 156)